Profile photo Emile Voest

Emile Voest

Full Professor

Biography

Emile Voest is professor of Medical Oncology, senior group leader at the Netherlands Cancer Institute, senior scientist of the Oncode Institute, and translational scientist. He is the current chair of the board of directors of Cancer Core Europe, a collaboration of 7 excellent comprehensive cancer centers. Until 2021, he served as executive medical director of the Netherlands Cancer Institute. He is also an independent, non-executive board member of Sanofi, is co-founder and serves on the non-executive board of the Hartwig Medical Foundation. He recently has co-founded Mosaic Therapeutics, devoted to developing new combinatorial treatments in a specific genomic background.

 

His academic group is devoted to bringing precision medicine to patients and is focused on large scale genomic sequencing of patients with metastatic cancer, the development of co-culture models of primary cultures of tumors (i.c. organoids) and immune cells to improve drug development and immunotherapy and to determine which treatment is best for a specific patient via computational, integrated approaches.

Recent publications

Trametinib for NRAS-mutated tumors Florentine A J Verbeek, Miguel P Martinez, Ilse A C Spiekman, Karlijn Verkerk, Soemeya F Haj Mohammad, Hans Timmer, Maud A van Maren, Laurien J Zeverijn, Birgit S Geurts, Vincent van der Noort, Paul Roepman, Anne M L Jansen, Wendy W J de Leng, Willemijn S M E Theelen, Berber Piet, Hans Gelderblom, Henk M W Verheul, Emile E Voest
European Journal of Cancer, 2026, vol. 244
Microbiota-derived metabolites as modulators of cancer immunotherapy response Catherine Toner-Bartelds, Iris L Mimpen, Miguel Parra-Martinez, Boudewijn M T Burgering, Emile E Voest
Nature Communications, 2026, vol. 17
The SHERPA trial Ashwini C Kanhailal, Jonathan E Knikman, Sybrand W J Zielhuis, Liudmila L Kodach, René Bernards, Alwin D R Huitema, Matthijs Tibben, Emile E Voest, Brent M Gerrits, Hinke Huisman-Siebinga, Neeltje Steeghs, Sara Mainardi, Frans L Opdam
European Journal of Cancer, 2026, vol. 241
Prospective evaluation of genomics-guided off-label treatment K. Verkerk, A. C. Spiekman, S. F. Haj Mohammad, F. A.J. Verbeek, H. Timmer, M. A. van Maren, L. J. Zeverijn, B. S. Geurts, V. van der Noort, P. Roepman, A. M.L. Jansen, W. W.J. de Leng, H. Gelderblom, H. M.W. Verheul, E. E. Voest, F. Jeurissen, M. A. Davidis-van Schoonhoven, S. C.S. Tromp, E. Siemerink, E. N. Klein Hesselink, S. Boudewijns, M. Los, J. W.B. de Groot, M. P. Hendriks, S. Hovenga, P. de Mol, J. A.J. Douma, H. P. van den Berg, A. L.T. Imholz, D. Houtsma, M. van Rooijen, F. van den Berkmortel, A. Vulink, T. van Voorthuizen, G. J. de Klerk, G. Vreugdenhil, E. Boon, A. P. Hamberg, A. D. Bins, H. M. Westgeest, E. D. Kerver, L. V. Beerepoot, H. Gelderblom, A. Hoeben, C. van Herpen, D. J.A. de Groot, M. Labots, J. M. van Dodewaard-de Jong, H. H. Nienhuis,
Nature, 2026, vol. 653, p.558–566
Corrigendum to Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance Ron Cj Schackmann, Miranda van Amersfoort, Judith Hi Haarhuis, Eva J Vlug, Vincentius A Halim, Jeanine Ml Roodhart, Joost S Vermaat, Emile E Voest, Petra van der Groep, Paul J van Diest, Jos Jonkers, Patrick WB Derksen
The Journal of clinical investigation, 2026, vol. 136
BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol Soemeya F Haj Mohammad, Ilse A C Spiekman, Karlijn Verkerk, Florentine A J Verbeek, Hans Timmer, Maud A van Maren, Laurien J Zeverijn, Birgit S Geurts, Antonios Daletzakis, Paul Roepman, Anne M L Jansen, Wendy W J de Leng, Sybren L N Maas, Filip Y F L de Vos, Henk M W Verheul, Emile E Voest, Hans Gelderblom
European Journal of Cancer, 2026, vol. 238